Irbesartan Actavis

Irbesartan, the active ingredient in Irbesartan Actavis, is an angiotensin II receptor blocker (ARB) presented as an oral tablet for systemic use. It lowers elevated blood pressure and slows progression of kidney damage in patients with diabetes, acting by selectively inhibiting angiotensin II type 1 receptors. The medication is indicated for adults with primary hypertension and for those with diabetic nephropathy, providing a targeted approach to cardiovascular and renal protection.

GNH USA supplies Irbesartan Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan is used to manage conditions related to the renin‑angiotensin system, primarily hypertension and diabetic kidney disease.

Hypertension: lowers systolic and diastolic blood pressure, reducing the risk of stroke, myocardial infarction, and other cardiovascular events. Diabetic nephropathy: slows the decline of renal function in patients with type 2 diabetes, helping to preserve kidney health.

Irbesartan may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate pain in the head region. - Fatigue: unusual tiredness or lack of energy. - Upper respiratory tract infection: symptoms such as sore throat, nasal congestion, or cough. - Nausea: feeling of sickness in the stomach. - Diarrhea: loose, watery stools.

Serious or Rare Side Effects: - Hyperkalemia: elevated blood potassium that can affect heart rhythm. - Angioedema: swelling of the face, lips, tongue, or throat, potentially compromising airway. - Acute renal failure: sudden loss of kidney function requiring medical attention. - Hypotension: marked drop in blood pressure leading to faintness.

When prescribing irbesartan, clinicians should consider several precautionary measures to ensure safe use. - Renal function: assess baseline creatinine and monitor periodically. - Electrolytes: check serum potassium before initiation and during therapy. - Pregnancy: avoid use in the second and third trimesters due to potential fetal harm. - Concomitant drugs: review for potassium‑sparing agents or NSAIDs that may increase adverse effects. - Hypersensitivity: discontinue if signs of angioedema or rash appear. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original container.

Irbesartan can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Potassium‑sparing diuretics (e.g., spironolactone): risk of severe hyperkalaemia. - ACE inhibitors or other ARBs: additive blood pressure lowering, possible renal impairment. - Aliskiren in diabetic patients: increased risk of renal dysfunction and hyperkalaemia.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may reduce antihypertensive effect and affect renal function. - Lithium: may increase lithium levels; monitor for toxicity. - Cyclosporine: can raise irbesartan concentrations; monitor blood pressure and renal function.